Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.

Verified December 2007 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00262782

First received: December 6, 2005

Last updated: November 5, 2013

Last verified: December 2007

History of Changes

Purpose

RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Sometimes, the cancer may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether fludarabine is more effective than observation in treating chronic lymphocytic leukemia.

PURPOSE: This randomized phase III trial is studying fludarabine to see how well it works compared to observation only in treating patients with stage 0, stage I, or stage II B-cell chronic lymphocytic leukemia.

Condition	Intervention	Phase
Leukemia	Drug: fludarabine phosphate	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Primary Purpose: Treatment
Official Title:	Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia

Resource links provided by NLM:

MedlinePlus related topics: Chronic Lymphocytic Leukemia Leukemia

Drug Information available for: Fludarabine Fludarabine phosphate

Genetic and Rare Diseases Information Center resources: Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic Squamous Cell Carcinoma of the Head and Neck

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):


Study Start Date:	April 1997

Detailed Description:

OBJECTIVES:

Identify prognostic factors that predict a short survival in patients with stage 0-II B-cell chronic lymphocytic leukemia treated with fludarabine or observation only.

OUTLINE: This is a randomized study. Patients are stratified according to risk (high risk vs low risk). Patients in the low-risk group undergo observation only. Patients in the high-risk group are randomized to 1 of 2 treatment arms.

Arm I: Patients receive fludarabine.
Arm II: Patients undergo observation only.

PROJECTED ACCRUAL: A total of 880 patients will be accrued for this study.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Confirmed diagnosis of B-cell chronic lymphocytic leukemia
- Rai stage 0-II (Binet stage A) disease
Meets 1 of the following criteria:
- High-risk disease, as defined by the following:
  - Serum thymidine kinase level > 7.0 U/L
  - Elevated β2-microglobulin level
  - Presence of non-nodular bone marrow infiltration
  - Short lymphocyte doubling time
- Low-risk disease
  - Meets none of the criteria (as listed above) for high-risk disease

PATIENT CHARACTERISTICS:

Performance status

Not specified

Life expectancy

More than 6 months

Hematopoietic

No autoimmune hemolytic anemia
No thrombocytopenia

Hepatic

Not specified

Renal

Not specified

Other

No severe organ dysfunction
No other prior or concurrent malignancy

PRIOR CONCURRENT THERAPY:

Chemotherapy

No prior chemotherapy
No other concurrent chemotherapy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00262782

Show 117 Study Locations

Sponsors and Collaborators

German CLL Study Group

Investigators


Study Chair:	Michael Hallek, MD	Medizinische Universitaetsklinik I at the University of Cologne

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Bergmann MA, Eichhorst BF, Busch R, et al.: Early and risk-adapted therapy with fludarabine in high-risk Binet stage A CLL patients prolongs progression free survival but not overall survival: results of the CLL1 protocol of the German CLL Study Group (GCLLSG). [Abstract] Blood 110 (11): A-2038, 2007.

Bergmann MA, Eichhorst BF, Busch R, et al.: Prospective evaluation of prognostic parameters in early stage chronic lymphocytic leukemia (CLL): results of the CLL1-protocol of the German CLL Study Group (GCLLSG). [Abstract] Blood 110 (11): A-625, 2007.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5.


ClinicalTrials.gov Identifier:	NCT00262782 History of Changes
Other Study ID Numbers:	CDR0000455035, GCLLSG-CLL1, EU-20548, GCLLSG-138, MEDAC-GCLLSG-CLL1
Study First Received:	December 6, 2005
Last Updated:	November 5, 2013
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):


B-cell chronic lymphocytic leukemia stage 0 chronic lymphocytic leukemia stage I chronic lymphocytic leukemia stage II chronic lymphocytic leukemia

Additional relevant MeSH terms:


Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Immune System Diseases Immunoproliferative Disorders Leukemia, B-Cell Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Fludarabine	Fludarabine phosphate Antimetabolites Antimetabolites, Antineoplastic Antineoplastic Agents Immunologic Factors Immunosuppressive Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Therapeutic Uses

ClinicalTrials.gov processed this record on February 25, 2015

To Top